Literature DB >> 29169164

A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).

Muna Ghazzawi1, Varun Mehra, Marcin Knut, Loretta Brown, William Tapper, Andrew Chase, Hugues de Lavallade, Nicholas C P Cross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29169164     DOI： 10.1159/000484077

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  2 in total

1.  Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

Authors:  Monica Kasbekar; Valentina Nardi; Paola Dal Cin; Andrew M Brunner; Meghan Burke; Yi-Bin Chen; Christine Connolly; Amir T Fathi; Julia Foster; Molly Macrae; Steven L McAfee; Kristin McGregor; Rupa Narayan; Aura Y Ramos; Tina T Som; Meghan Vartanian; Robb S Friedman; Karim A Benhadji; Gabriela S Hobbs
Journal:  Blood Adv       Date:  2020-07-14

2.  What went wrong with variant effect predictor performance for the PCM1 challenge.

Authors:  Maximilian Miller; Yanran Wang; Yana Bromberg
Journal:  Hum Mutat       Date:  2019-07-03       Impact factor: 4.700
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.